Fisher Asset Management LLC boosted its holdings in shares of Core Laboratories Inc. (NYSE:CLB – Free Report) by 19.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 990,267 shares of the oil and gas company’s stock after purchasing an additional 161,278 shares during the quarter. Fisher Asset Management LLC owned about 2.11% of Core Laboratories worth $18,350,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in CLB. Headlands Technologies LLC bought a new stake in shares of Core Laboratories during the second quarter valued at approximately $36,000. nVerses Capital LLC purchased a new stake in Core Laboratories in the 3rd quarter worth $48,000. GAMMA Investing LLC boosted its holdings in shares of Core Laboratories by 23.9% during the 2nd quarter. GAMMA Investing LLC now owns 4,425 shares of the oil and gas company’s stock valued at $90,000 after purchasing an additional 855 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of Core Laboratories by 11.9% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 5,636 shares of the oil and gas company’s stock valued at $114,000 after purchasing an additional 600 shares in the last quarter. Finally, Signaturefd LLC increased its holdings in shares of Core Laboratories by 12.8% in the second quarter. Signaturefd LLC now owns 6,776 shares of the oil and gas company’s stock worth $137,000 after purchasing an additional 767 shares during the last quarter. 97.81% of the stock is owned by hedge funds and other institutional investors.
Core Laboratories Trading Down 0.6 %
Shares of CLB stock opened at $20.43 on Thursday. The company has a market cap of $959.19 million, a PE ratio of 31.43, a price-to-earnings-growth ratio of 1.40 and a beta of 2.35. Core Laboratories Inc. has a 1 year low of $13.82 and a 1 year high of $25.13. The stock’s 50 day simple moving average is $19.38 and its two-hundred day simple moving average is $19.52. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.48 and a quick ratio of 1.79.
Core Laboratories Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Monday, November 4th were issued a dividend of $0.01 per share. The ex-dividend date was Monday, November 4th. This represents a $0.04 annualized dividend and a yield of 0.20%. Core Laboratories’s payout ratio is 6.15%.
Analysts Set New Price Targets
Several equities analysts have weighed in on the company. StockNews.com upgraded Core Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Citigroup cut their target price on shares of Core Laboratories from $15.00 to $14.00 and set a “sell” rating for the company in a report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating and three have assigned a hold rating to the stock. According to data from MarketBeat.com, Core Laboratories presently has an average rating of “Hold” and an average price target of $17.00.
View Our Latest Research Report on Core Laboratories
Core Laboratories Profile
Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.
Featured Articles
- Five stocks we like better than Core Laboratories
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Effectively Use the MarketBeat Ratings Screener
- 2 Generic Drug Stocks Ready to Surge in 2025
Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories Inc. (NYSE:CLB – Free Report).
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.